Accelerating access to modern medical care
Tackling some of the most pressing healthcare challenges facing our societies today must be one of our biggest priorities.
We are focused on accelerating access to modern medical care for those who need it most, while addressing unmet medical needs in developing markets around the world.
Access to health should be a basic human right. An individual’s birthplace, proximity to infrastructure or lack of wealth should not deny that access, and yet for many communities, that is the everyday reality. The Jameel family’s commercial and non-commercial interests in the health sector reflect this ethos of inclusivity.
Rare Disease & Specialty Therapeutics
Abdul Latif Jameel invests in addressing some of the worlds rare diseases through independent specialty pharmaceutical business.
This focus has a particular emphasis on neuromuscular, lysosomal storage disease and ophthalmology, dermatology, and more. The portfolio also encompasses leading therapies for women’s health and specialty care as well as central nervous system disorders.
These businesses were amongst the first to bring gene therapy to the Middle East region. By partnering with biotechnology leaders and pioneers in the field, this has accelerated access to innovative cures and treatments to patients across MENA.
Rehabilitation
Inaugurated in 1997, and covering 43,000m2, including eight wards with 120 beds and extensive gardens, the Abdul Latif Jameel Hospital was the first healthcare facility of its kind pioneering medical rehabilitation in Saudi Arabia.
The Abdul Latif Jameel Hospital has helped over 95,000 patients and offers comprehensive and distinctive rehabilitation programs for adults and children including intensive day-care, recreational therapy programs for the inpatients, an autism care program, outpatient treatment, medical services, and home care.
Harnessing innovative technologies in healthcare space, the Abdul Latif Jameel Hospital became a pioneer in the use of Cyberdyne robotic exoskeletons for the treatment of spinal injury. An initiative which has led to us being the distributor for the GCC region and a regional training center.
In 2025, the Abdul Latif Jameel Hospital celebrated its 30th anniversary.
Philanthropy & Advanced Research
The Jameel family’s long-established philanthropy, Community Jameel, and its focus on furthering science to help communities thrive in a rapidly changing world, also encompasses advancing the future of health.
In 2018, Community Jameel co-founded of the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) at MIT, and in 2019, the Abdul Latif Jameel institute for Disease & Emergency Analytics (Jameel Institute) at Imperial College London.
The MIT Jameel Clinic drives the creation of high-precision, affordable and scalable AI technologies to revolutionize healthcare across the key areas: clinical AI, drug discovery, and epidemiology.
It is working on novel algorithms for modelling biological and clinical data, while striving toward new discoveries in machine learning, biology, chemistry and clinical sciences. This research led to significant breakthroughs including new antibiotics halicin and abaucin, and clinical AI tools, such as MIRAI and SYBIL.
The Jameel Institute brings together researchers from multiple disciplines to utilize expertise in data analytics to help combat disease threats worldwide.
The Institute improves our understanding of disease across populations linking governments, research institutions, and communities, to develop effective long-term solutions, shape health policy and ultimately, deliver a better quality of life.
The Institute has three main research themes: responding to health emergencies, strengthening health systems, and building partnerships and capacity.
